Paul Grint

Here at CRISPR QC, we empower scientists using CRISPR to solve the world’s great challenges by providing the key cornerstones of information and insight fundamental to realizing the full potential of CRISPR.

Inhibikase Therapeutics (Nasdaq: IKT) is a clinical-stage pharmaceutical company focused on developing and commercializing small-molecule kinase inhibitor therapeutics that modify Parkinson's disease and drive functional reversal inside and outside of the brain. Inhibikase is headquartered in Atlanta, Georgia with additional offices in Boston, Massachusetts.

Persephone is pioneering the use of synthetic biology for microbial products that impact patient and infant health. We are building an end-to-end platform to industrialize the development of engineered cells that restore health to damaged human ecosystems. The company was founded in the summer of 2017 by synthetic and metabolic engineering pioneers, Stephanie Culler PhD, and Steve Van Dien PhD.

Amplyx was founded on a mission to save lives by developing a new class of antifungal medicine that would overcome the severe limitations of today’s therapeutic options. We are developing first-in-class products for the treatment of life-threatening infections, with a near-term focus on deadly fungal pathogens in vulnerable, immune-compromised patients. Amplyx’s leadership has extensive experience developing drugs to treat infectious diseases, as well as treatments for rare conditions. For more information on Amplyx, please visit our website at www.amplyx.com

A forward-thinking, medical technology company dedicated to developing life-saving products and therapies that encourage healing, reduce complications of tissue damage and inflammation, prevent infection by drug-resistant bacteria and remove the biofilms in which they thrive. We use the best of nature to solve important, real-time problems.

At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina’s innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.

Here at CRISPR QC, we empower scientists using CRISPR to solve the world’s great challenges by providing the key cornerstones of information and insight fundamental to realizing the full potential of CRISPR.

Inhibikase Therapeutics (Nasdaq: IKT) is a clinical-stage pharmaceutical company focused on developing and commercializing small-molecule kinase inhibitor therapeutics that modify Parkinson's disease and drive functional reversal inside and outside of the brain. Inhibikase is headquartered in Atlanta, Georgia with additional offices in Boston, Massachusetts.

Persephone is pioneering the use of synthetic biology for microbial products that impact patient and infant health. We are building an end-to-end platform to industrialize the development of engineered cells that restore health to damaged human ecosystems. The company was founded in the summer of 2017 by synthetic and metabolic engineering pioneers, Stephanie Culler PhD, and Steve Van Dien PhD.

Amplyx was founded on a mission to save lives by developing a new class of antifungal medicine that would overcome the severe limitations of today’s therapeutic options. We are developing first-in-class products for the treatment of life-threatening infections, with a near-term focus on deadly fungal pathogens in vulnerable, immune-compromised patients. Amplyx’s leadership has extensive experience developing drugs to treat infectious diseases, as well as treatments for rare conditions. For more information on Amplyx, please visit our website at www.amplyx.com

A forward-thinking, medical technology company dedicated to developing life-saving products and therapies that encourage healing, reduce complications of tissue damage and inflammation, prevent infection by drug-resistant bacteria and remove the biofilms in which they thrive. We use the best of nature to solve important, real-time problems.